The messenger : Moderna, the vaccine, and the business gamble that changed the world / Peter Loftus.
By: Loftus, Peter (Peter D.) [author.].
Publisher: Boston, Massachusetts : Harvard Business Review Press, ©2022Description: 306 p.Content type: text Media type: unmediated Carrier type: volumeISBN: 9781647823191.Subject(s): Moderna (Firm) -- History | Vaccines industry -- History | Pharmaceutical biotechnology industry -- Economic aspects -- History | Messenger RNAGenre/Form: Print books.Current location | Call number | Status | Date due | Barcode | Item holds |
---|---|---|---|---|---|
On Shelf | HD9675.V334 M645 2022 (Browse shelf) | Available | AU00000000018635 |
Browsing Alfaisal University Shelves , Shelving location: On Shelf Close shelf browser
HD9666.6 .E68 2008 Overdose : how excessive government regulation stifles pharmaceutical innovation / | HD9666.94 .K444 2021 Empire of pain : the secret history of the Sackler dynasty / | HD9675.O643 U64 2022 American cartel : inside the battle to bring down the opioid industry / | HD9675.V334 M645 2022 The messenger : Moderna, the vaccine, and the business gamble that changed the world / | HD9681.A2 C43 2019 Solar power finance without the jargon / | HD9685 .U5 F748 2017 When they hid the fire : a history of electricity and invisible energy in America / | HD9696.A3 U5757 2005 The HP way : how Bill Hewlett and I built our company / |
Includes index.
Prologue. Disease X -- Changing the Fate -- If This Is True -- Kendall Square -- Feeding the Beast -- Broke Offer -- No Boundaries -- mRNA- -- More Money -- Warp Speed -- Hold On, Help Is On the Way -- Politics Protocols and Patents -- The Power of Science -- Evidence -- Happy Tears -- Delta -- Just the Beginning.
"At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of a potentially breakthrough innovation: using RNA to combat disease. Investors were getting antsy or, worse, skeptical. Then the coronavirus pandemic hit, and Moderna became a central player in a global drama-a David to pharma's Goliaths-turning its technology toward breaking the global grip of the terrible disease. By year's end, as the outbreak was at its worst, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement not only offered the world a way out of a crippling pandemic but also validated Moderna's gene-based technology, transforming the company into a global industry power, swelling its market value on its prospects for new drugs and vaccines for years to come. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, part of a Pulitzer Prize-finalist reporting team and 25-year veteran reporter in the pharmaceutical and biotech industries, brings the inside story of how Moderna went all in on a single revolutionary idea; of quiet research with unknown consequence; of the evolution of a cutting-edge American innovation, industry, and economy-decades in the making-that led to one of the great gambles in business history"--